Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam

Fundamental and Clinical Pharmacology

Volumn 27, Issue 6, 2013, Pages 698-710

  Dingemanse, Jasper ^a   Nicolas, Laurent ^a   Binkert, Christoph ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

ACT 178882; Midazolam and food interaction; Pharmacodynamics; Pharmacokinetics; Renin inhibitor

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ACT 178882; ALDOSTERONE; CREATININE; CYTOCHROME P450 3A4; ENALAPRIL; FUROSEMIDE; HYDROCORTISONE; MIDAZOLAM; POTASSIUM; RENIN; RENIN INHIBITOR; SODIUM; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; BLURRED VISION; BODY WEIGHT; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; EPIGASTRIC DISCOMFORT; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; LETHARGY; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE TWITCH; MYALGIA; NORMAL HUMAN; PHARMACODYNAMICS; PLASMA RENIN ACTIVITY; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VITAL SIGN;

ACT-178882; MIDAZOLAM AND FOOD INTERACTION; PHARMACODYNAMICS; PHARMACOKINETICS; RENIN INHIBITOR;

ADULT; AREA UNDER CURVE; BLOOD PRESSURE; CYCLOPROPANES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENALAPRIL; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDAZOLAM; PYRIDINES; RENIN; TIME FACTORS; YOUNG ADULT;

EID: 84886593187     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01060.x     Document Type: Article

References (27)

1. Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. Lancet (2005) 365 217-223.
2. Gupta R., Guptha S. Strategies for initial management of hypertension. Indian J. Med. Res. (2010) 132 531-542.
3. Hollenberg N.K., Fisher N.D. Renal circulation and blockade of the renin-angiotensin system Is angiotensin-converting enzyme inhibition the last word? Hypertension (1995) 26 602-609.
4. Fisher N.D., Jan Danser A.H., Nussberger J. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation (2008) 117 3199-3205.
5. Cagnoni F., Njwe C.A., Zaninelli A. et al. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc. Health Risk Manag. (2010) 6 549-559.
6. Ravandi A., Teo K.K. Blocking the renin-angiotensin system: dual- versus mono-therapy. Expert Rev. Cardiovasc. Ther. (2009) 7 667-674.
7. ® in high-risk patients with diabetes and renal impairment. Media Release, December 20, 2011. http://www.novartis.com/newsroom/media-releases/en/2011/1572562. shtml
8. Fisher N.D., Hollenberg N. Is there a future for renin inhibitors? Expert Opin. Investig. Drugs (2001) 10 417-426.
9. Rongen G.A., Lenders J.W., Smits P., Thien T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin. Pharmacokinet. (1995) 29 6-14.
10. Corminboeuf O., Bezencon O., Remen L. et al. Piperidine-based renin inhibitors: upper chain optimization. Bioorg. Med. Chem. Lett. (2010) 20 6291-6296.
11. Bjornsson T.D., Callaghan J.T., Einolf H.J. et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. (2003) 31 815-832.
12. Nicolas L.B., Binkert C., Mant T. et al. Integrated clinical pharmacology of single and multiple ascending doses of ACT-178882/MK-1597, a new renin inhibitor. 38th Annual Meeting of the American College of Clinical Pharmacology, San Antonio, TX, 2009, September 13-15. J. Clin. Pharmacol. (2009) 49 1110.
13. Olkkola K.T., Ahonen J. Midazolam and other benzodiazepines. Handb. Exp. Pharmacol. (2008) 182 335-360.
14. Campbell D.J., Nussberger J., Stowasser M. et al. Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin. Chem. (2009) 55 867-877.
15. Menard J., Boger R.S., Moyse D.M. et al. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation (1995) 91 330-338.
16. Gough K., Hutchison M., Keene O. et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf. J. (1995) 29 1039-1048.
17. Ali A.K. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther. Clin. Risk Manag. (2011) 7 337-344.
18. Tekturna® (aliskiren tablets): US prescribing information, Novartis, East Hannover, 2011.
19. Eisen S.A., Miller D.K., Woodward R.S. et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med. (1990) 150 1881-1884.
20. Greenblatt D.J., von Moltke L.L., Harmatz J.S. et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther. (2003) 74 121-129.
21. Olkkola K.T., Backman J.T., Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. (1994) 55 481-485.
22. Galteau M.M., Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur. J. Clin. Pharmacol. (2003) 59 713-733.
23. Nussberger J., Wuerzner G., Jensen C. et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 39 E1-E8.
24. Vander A.J., Greelhoed G.W. Inhibition of renin secretion by Ang II. Proc. Soc. Exp. Biol. Med. (1965) 120 339-403.
25. Neutel J.M. The importance of 24-h blood pressure control. Blood Press. Monit. (2001) 6 9-16.
26. Morganti A., Lonati C. Aliskiren: the first direct renin inhibitor available for clinical use. J. Nephrol. (2011) 24 541-549.
27. Stanton A., Jensen C., Nussberger J. et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 42 1137-1143.